Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Almut Scherer

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Clinical Rheumatology|March 10, 2025
Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohortAnnik Steimer, Andrea Götschi, Torsten Witte, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAdrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, et al.
RMD Open|July 28, 2023
Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 yearsCaroline Ensslin, Raphael Micheroli, Seraphina Kissling, et al.
RMD Open|February 3, 2022
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohortAdrian Ciurea, Seraphina Kissling, Kristina Bürki, et al.
Clinical Rheumatology|June 8, 2023
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management RegistryRaphael Micheroli, Seraphina Kissling, Kristina Bürki, et al.
Scientific Reports|October 18, 2023
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical careMyriam Riek, Almut Scherer, Burkhard Möller, et al.
Frontiers in Immunology|October 31, 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesCatherine E Raptis, Christoph T Berger, Adrian Ciurea, et al.
Rheumatology (Oxford, England)|October 21, 2019
Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three yearsBurkhard Möller, Daniel Aletaha, Michael Andor, et al.
Annals of the Rheumatic Diseases|September 24, 2017
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohortChristoph Molnar, Almut Scherer, Xenofon Baraliakos, et al.
Arthritis and Rheumatism|August 29, 2013
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohortAdrian Ciurea, Almut Scherer, Pascale Exer, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Clinical Rheumatology|March 10, 2025
Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohortAnnik Steimer, Andrea Götschi, Torsten Witte, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAdrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, et al.
RMD Open|July 28, 2023
Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 yearsCaroline Ensslin, Raphael Micheroli, Seraphina Kissling, et al.
RMD Open|February 3, 2022
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohortAdrian Ciurea, Seraphina Kissling, Kristina Bürki, et al.
Clinical Rheumatology|June 8, 2023
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management RegistryRaphael Micheroli, Seraphina Kissling, Kristina Bürki, et al.
Scientific Reports|October 18, 2023
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical careMyriam Riek, Almut Scherer, Burkhard Möller, et al.
Frontiers in Immunology|October 31, 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesCatherine E Raptis, Christoph T Berger, Adrian Ciurea, et al.
Rheumatology (Oxford, England)|October 21, 2019
Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three yearsBurkhard Möller, Daniel Aletaha, Michael Andor, et al.
Annals of the Rheumatic Diseases|September 24, 2017
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohortChristoph Molnar, Almut Scherer, Xenofon Baraliakos, et al.
Arthritis and Rheumatism|August 29, 2013
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohortAdrian Ciurea, Almut Scherer, Pascale Exer, et al.
Pageof 6